CARY, N.C.--(BUSINESS WIRE)--The CEO Roundtable on Cancer elected Robert A. Bradway as its Chairman at its recent annual meeting, CEO Roundtable-XIV. Mr. Bradway, chairman and chief executive officer of Amgen, will serve a three-year term.
The CEO Roundtable on Cancer, a nonprofit organization of executives, was founded by former President George H.W. Bush in 2001 with a mandate to bring bold and imaginative solutions to cancer treatment and prevention. This CEO-led effort has benefitted from a fourteen-year legacy of strong leadership, beginning with President Bush’s appointments of former Chairs Robert A. Ingram, William C. Weldon and Christopher A. Viehbacher.
“The CEO Roundtable on Cancer is committed to the elimination of cancer as a public health issue,” said Bradway. “Our hope is that through powerful initiatives like the CEO Cancer Gold Standard accreditation and Project Data Sphere, LLC, we can facilitate better access to the best-available treatments, advance research and enhance prevention efforts.”
The CEO Roundtable on Cancer has led efforts in both global health and research innovation, as well as its deep commitment to employee wellness through its CEO Cancer Gold Standard workplace accreditation program. The Gold Standard recognizes employers’ efforts to build a culture of wellness by promoting healthy lifestyle choices, encouraging cancer screening and promoting access to quality cancer treatment.
Globally, CEOs from many industries are keenly aware of the life-improving impact they can have on both health and controlling healthcare costs when they address cancer and other chronic diseases. In 2012, under the chairmanship of Chris Viehbacher, the CEO Roundtable on Cancer began working in China with government, industry and international cancer experts to bring the benefits of the Gold Standard to the world’s most populated country.
Also under Chairman Viehbacher’s leadership, the CEO Roundtable on Cancer’s Life Sciences Consortium in 2012 established Project Data Sphere, LLC, an independent not-for-profit initiative that created a clinical trial data sharing platform (www.ProjectDataSphere.org) to advance research. By April of 2015, the initiative celebrated a milestone by garnering more than 25,000 patient lives of data and welcoming a virtual research community of more than 1,000 researchers from 44 countries.
Organizations that have provided clinical trial data to this digital library-laboratory include: Amgen, AstraZeneca, Bayer, Celgene, EMD Serono, Johnson & Johnson, Eli Lilly, Memorial Sloan Kettering Cancer Center, Pfizer, Synta, Sanofi, and The Alliance for Clinical Trials in Oncology, one of the five U.S. network groups of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN). In order to ensure that researchers realize the full potential of the clinical trial data in the platform, Project Data Sphere, LLC teamed with CEO Roundtable on Cancer member SAS Institute Inc. (SAS), a leader in data and health analytics, to make state-of-the-art analytic tools freely available to all registered users within the Project Data Sphere environment.
In 2014, the CEO Roundtable on Cancer received the Global Health Impact Award from Project HOPE for its global health and wellness efforts through the Gold Standard accreditation program and its leadership in promoting and sharing critical clinical trial data in oncology.
“I am pleased to welcome Bob Bradway as the next chairman of the CEO Roundtable on Cancer,” said outgoing chairman Chris Viehbacher, managing partner of Gurnet Point Capital. “I look forward to working with Bob and to the continued progress we will surely make with his leadership and insight.”
About The CEO Roundtable on Cancer
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard™ which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. The Life Sciences Consortium (LSC) was formed by the CEO Roundtable on Cancer as a means of bringing together leading oncology pharmaceutical/biotechnology companies to collaborate on solving issues common to all organizations engaged in drug discovery and development that cannot be solved by any single entity alone. For more information, please visit www.CEORoundtableOnCancer.org.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.